PF-06865571
Protocol C2541007Final Protocol, 11 Dec 2020
PFIZER CONFIDENTIAL
Page 1A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY IN HEALTHY 
ADULT MALE PARTICIPANTS TO ASSESS THE EXTENT OF EXCRETION, 
ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND 
PHARMACOKINETICS OF [14C]PF-06865571 USING A 14C-MICROTRACER 
APPROACH
Study Intervention Number: PF-06865571
Study Intervention Name: N/A
US IND Number:
EudraCT Number: N/A
Protocol Number: C2541007
Phase: Phase 1
Short Title: A Study in Healthy Adult Male Participants to Assess ADME Properties of
[14C]PF-06865571
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.
CCI
PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary and Rationale for Changes
Original protocol 11Dec 2020 N/A

PF-[ADDRESS_584812] OF FIGURES ...................................................................................................................7
1. PROTOCOL  SUMMARY .....................................................................................................8
1.1. Sy nopsis ....................................................................................................................8
1.2. Schema ......................................................................................................................8
1.3. Schedule of Activities ...............................................................................................9
2. INTRODUCTION ...............................................................................................................15
2.1. Study  Rationale .......................................................................................................15
2.2. Backgro
und .............................................................................................................15
2.2.1. Nonclinical Pharmacokinetics and Metabolism .........................................15
2.2.2. Clinical Overview .......................................................................................16
[IP_ADDRESS]. Summary  of Clinical Safet y
......................................................16
[IP_ADDRESS]. Summary  of Clinical Pharmacology .........................................16
2.3. Benefit/Risk Assessment
.........................................................................................17
2.3.1. Risk Assessment
.........................................................................................18
2.3.2. Benefit Assessment .....................................................................................20
2.3.3. Overall Benefit/Risk Conclusion ................................................................20
3. OBJECTI
VES AND EN DPOINTS .....................................................................................20
4. STUDY DESIGN .................................................................................................................21
4.1. Overall Design .........................................................................................................21
4.2. Scientific Rationale for Study  Design .....................................................................22
4.3. Justification for Dose ..............................................................................................23
4.4. End of Study  Definition ..........................................................................................24
5. STUDY POPUL ATION
................................ ................................ ................................ ......24
5.1. I nclusion Criteria .....................................................................................................24
5.2. Exclu sion Criteria ....................................................................................................25
5.3. L ifesty le Considerations ..........................................................................................27
5.3.1. Meals and Dietary  Restrictions ...................................................................27
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................29
5.3.3. Activity .......................................................................................................29

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 45.4. Screen Failures ........................................................................................................29
6. STUDY INTERVENTIO N
..................................................................................................29
6.1. Study  Intervention(s) Administered ........................................................................29
6.1.1. Administration ............................................................................................30
6.2. Prepara tion/Handling/Storage/Accountability ........................................................30
6.2.1. Preparation and Dispensing ........................................................................31
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................32
6.3.1. Allocation to Study Intervention ................................................................32
6.4. Study  Intervention Compliance ...............................................................................32
6.5. Concomitant Therapy ..............................................................................................32
6.5.1. Rescue Medicine .........................................................................................33
6.6. Dose Modification ...................................................................................................33
6.7. I ntervention After the End of the Study ..................................................................33
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................33
7.1.Discontinuation of Study  Intervention ....................................................................33
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_584813] to Follow up
....................................................................................................35
8. STUDY A SSESSMENTS AND PROCE DURES ...............................................................35
8.1. Efficacy  Assessments ..............................................................................................36
8.2. Safet y Assessments .................................................................................................36
8.2.1. Phy sical Examinations ................................................................................36
8.2.2. Vital Signs ..................................................................................................37
8.2.3. Electrocardiograms
.....................................................................................37
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................38
8.2.5. COVID -
19 Specific Assessments................................ ............................... 39
8.3. Adverse Events and Serious Adverse Events..........................................................39
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......39
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................40
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................40
8.3.2. Method of Detecting AEs and SAEs ................................ .......................... 40

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 58.3.3. Follow -up of AEs and SAEs .......................................................................40
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................41
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ..........................................................................................................41
[IP_ADDRESS]. Exposure During Pregnancy ......................................................41
[IP_ADDRESS]. Exposure During Breastfeeding ................................................43
[IP_ADDRESS]. Occupational Exposure .............................................................43
8.3.6. Cardiovascular and Death Events ...............................................................43
8.3.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_584814] .............................................................43
[IP_ADDRESS]. Lack of Efficacy ........................................................................44
8.3.9. Medical Device Deficiencies ......................................................................44
8.3.10. Medication Errors .....................................................................................44
8.4. Treatment of Overdose
............................................................................................44
8.5. Pharmacokinetics ....................................................................................................45
8.5.1. Period 1 Plasma for Anal ysis of Total 14C and Metabolite 
Profiling/ID ......................................................................................................45
8.5.2. Period 2 Plasma for Anal ysis of [14C]PF- 06865571 ( After IV
Administration )................................................................................................46
8.5.3. Plasma for Anal ysis of Unlabeled PF -06865571 (Periods 1 and 2) ...........47
8.5.4. Urine for Anal ysis of Total 14C (Oral and IV) and Metaboli
te
Profiling/ID ......................................................................................................47
8.5.5. Feces for Anal ysis of Total 14C (Oral and IV) and Metaboli
te
Profiling/ID ......................................................................................................48
8.5.6. Emesis
.........................................................................................................48
8.6. Pharmacod ynamics ..................................................................................................48
8.7.Genetics ...................................................................................................................49
8.7.1. Specified Gen etics ......................................................................................49
8.7.2. Banked Biospecimens for Genetics ................................ ............................ 49
8.8. Biomarkers ..............................................................................................................49
8.8.1. Specified Gene Expression (RNA) Research .............................................49
8.8.2. Specified Protein Research .........................................................................49

PF-06865571
Protocol C2541007Final Protocol, 11 Dec 2020
PFIZER CONFIDENTIAL
Page 68.8.3. Specified Metabolomic Research ...............................................................49
8.8.4. Banked Biospecimens for Biomarkers .......................................................49
8.9. Immunogenicity Assessments .................................................................................508.10. Health Economics .................................................................................................50
9. STATISTICAL C ONSIDERATIONS ................................................................................50
9.1. Statistical Hypotheses .............................................................................................509.2. Sample Size Determination.....................................................................................509.3. Analysis Sets ...........................................................................................................509.4. Statistical Analyses .................................................................................................51
9.4.1. Primary Endpoint(s)....................................................................................51
[IP_ADDRESS]. Extent of Excretion (Period 1) ..................................................[IP_ADDRESS]. Metabolic Profiling/Identification (Period 1)............................52
9.4.2. Secondary Endpoint(s)................................................................................52
[IP_ADDRESS]. Pharmacokinetic Parameters .....................................................52
9.4.3. Tertiary/Explorat ory Endpoint(s) ...............................................................55
[IP_ADDRESS]. Cumulative Rate of Excretion (Period 1)..................................55
[IP_ADDRESS]. Pharmacokinetics Parameters (Unlabeled PF-06865571 -
Period 2) ............................................................................................55
9.4.4. Other Safety Analyses ................................................................................559.4.5. Other Analyse(s).........................................................................................56
9.5. Interim Analyses .....................................................................................................569.6. Data Monitoring Committee or Other Independent Oversight Committee.............56
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................57
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............57
10.1.1. Regulatory and Ethical Considerations ....................................................57
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................57
10.1.2. Financial Disclosure .................................................................................58
10.1.3. Informed Consent Process ........................................................................58CCI
CCI
PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 710.1.4. Data Protection .........................................................................................59
10.1.5. Dissemination of Clinical Study  Data ......................................................59
10.1.6. Data Qualit y Assurance ............................................................................61
10.1.7. Source Documents ....................................................................................62
10.1.8. Study  and Site Start and Closure ..............................................................62
10.1.9. Publication Policy .....................................................................................63
10.1.10. Sponsor’s Qualified Medical Personnel .................................................64
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................65
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ......................................................................67
10.3.1. Definition of AE .......................................................................................67
10.3.2. Definition of SAE
.....................................................................................68
10.3.3. Recording/Reporting and Follow- up of AEs and/or SAEs .......................69
10.3.4. Reporting of SAEs
....................................................................................72
10.4. Appendix 4: Contraceptive Guidance ...................................................................74
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................74
10.5. Appendix 5: Genetics ............................................................................................75
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -up Assessments ........76
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................78
10.8. Appendix 
8: Abbreviations ...................................................................................[ADDRESS_584815] OF FIGURES
Figure 1. Two (2) -Period Fixed Sequence Study  Design ........................................21

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 81.PROTOCOL SUMMARY 
1.1.Synopsis 
Notapplicable .
1.2.Schema
Notapplicable .

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 91.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  sche dule visits (unplanned visits) in addi tion to those listed i n the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Visit Identifier Screening Period 1 (P1) and Period 2 (P2) , unless otherwise lim ited to 1 of these 2 PeriodsaF/U
Phone 
CallET
Days Relative to 
Day 1-42to -2 -1 1 2 3b45 67-21c≥28 -
35
days 
(P2 
only)-
Hours After Oral
PF-06865571 Dos e- - 00.5 1233.08 3.17 3.25 3.5 3.75 469121624273648 51 7296120 144-
504-
Hours After IV
[14C]PF-06865571 
Dose
(P2 Only)-3 00.08
3
(5 
min)0.17
(10 
min)0.25
(15
min)0.5
(30 
min)0.75
(45 
min)13691321243345 48
Informed Consent X
Inclusion/Exclusion 
CriteriaX X                  
Admission to the 
CRU (P1 only)X                       
CRU confinement X                   Xb,c   Xc
Medical/medication 
history (update) X X
Height and Weight X
Physical 
ExaminationdX XeX
Supi[INVESTIGATOR_050] 12 -lead 
ECGX X XeX
Supi[INVESTIGATOR_133634]
(Blood Pressure 
and Pulse Rate)X X XeX
COVID -19 
questionnairefX X

PF-06865571
Protocol C2541007Final Protocol, 11 Dec 2020
PFIZER CONFIDENTIAL
Page 10Visit Identifier Screening Period 1 (P1) and Period 2 (P2), unless otherwise limited to 1 of these 2 PeriodsaF/U
Phone 
CallET
Days Relative to 
Day 1-42 to -2 -1 1 2 3b45 67-21c≥28 -
35
days 
(P2 
only)-
Hours After Oral
PF-06865571 Dose- - 00.5 1233.08 3.17 3.25 3.5 3.75 469121624273648 51 7296120 144-
504-
Hours After IV
[14C]PF-06865571 
Dose
(P2 Only)-3 00.08
3
(5 
min)0.17
(10 
min)0.25
(15
min)0.5
(30 
min)0.75
(45 
min)13691321243345 48
COVID-19
temperature checkgXX Xh→→→→ → → → → → →→→→→→→  →→→  →→ → XX
Serious and Non-
serious Adverse Event MonitoringX→ → →→→→ → → → → → →→→→→→→  →→→  →→ → XXX
Standard MealsiXXiXX X X X X X X X
Oral 300 mg 
[14C]PF-06865571 
Administration(P1 Only)X
Oral 300 mg 
PF-06865571 
Administration(P2 only)X
IVinfusion 100 μg
[14C]PF-06865571 
Administration
(P2 Onl y)X→→ X
COVID-19 testingkXX  XXk
Emesis Collection 
for Radioactivity 
Measurement, if 
Occurs (P1 Only)X→→→→ → → → → → →→→→→ XCCI
PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 11Visit Identifier Screening Period 1 (P1) and Period 2 (P2) , unless otherwise lim ited to 1 of these 2 PeriodsaF/U
Phone 
CallET
Days Relative to 
Day 1-42to -2 -1 1 2 3b45 67-21c≥28 -
35
days 
(P2 
only)-
Hours After Oral
PF-06865571 Dos e- - 00.5 1233.08 3.17 3.25 3.5 3.75 469121624273648 51 7296120 144-
504-
Hours After IV
[14C]PF-06865571 
Dose
(P2 Only)-3 00.08
3
(5 
min)0.17
(10 
min)0.25
(15
min)0.5
(30 
min)0.75
(45 
min)13691321243345 48
Blood Sample Collection for -
PK of PF-
06865571 
following oral[14C] 
PF-06865571 in P1 
and unlabeled 
PF-06865571 in P2lX X X X X X X X X X X X XlX X X X
Total 
Radioa ctivitym
(P1 only)X X X X X X X X X X X X X X X X XmX
Metabolite
profiling/IDm
(P1 only)X X X X X X X X X X XmX
PK of IV infusion 
[14C]PF-06865571
(P2 Only)XnX X X X X X X X X X X X X X
Safetylaboratory X X XeX
HIV, HBsAg, 
HCVAbX
[COMPANY_007] Genomic 
Prep D1 .5Banked 
Biospecimen
(P1 Only)oX
[COMPANY_007] Prep B1
Banked 
Biospecimen
(P1 Only)oX

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 12Visit Identifier Screening Period 1 (P1) and Period 2 (P2) , unless otherwise lim ited to 1 of these 2 PeriodsaF/U
Phone 
CallET
Days Relative to 
Day 1-42to -2 -1 1 2 3b45 67-21c≥28 -
35
days 
(P2 
only)-
Hours After Oral
PF-06865571 Dos e- - 00.5 1233.08 3.17 3.25 3.5 3.75 469121624273648 51 7296120 144-
504-
Hours After IV
[14C]PF-06865571 
Dose
(P2 Only)-3 00.08
3
(5 
min)0.17
(10 
min)0.25
(15
min)0.5
(30 
min)0.75
(45 
min)13691321243345 48
Urine Sample collection for -
Spot Collection for 
Urine Drug 
Screening (P1 only)X X
Spot Collection for 
Urine Cotinine 
Screening
(P1only)X X
Spot Collection for 
Urinalysis (and 
Microscopy, i f 
needed)pX X XeX
Total Radioactivity 
and Metabolite 
profiling/ IDq
(P1 Only)XqX            X X  X X X X XoX
Total 
Radioactivityq
(P2 Only)X        X  X  Xq
Feces Sample collection for -
Total Radioactivity 
and Metabolite IDr
(P1 Only)XrX              X  X X X X XrX
[14C]PF -06865571r
(P2 Only)Xr           X  Xr
Abbreviations: = ongoing/continuous event; AE = adverse event; COVID -19 = Coronavirus disease 2019; CRU = Clinical Research Unit; ECG = electrocardiogram; ET=early 
termination; F/U=follow -up; HCVAb =hepatitis C antibody; HBsAg =hepatitis B surface antigen; HIV =human immunodeficiency virus; P1 = Period 1; P2 = Period 2; 
PK=pharmacokinetics ; SAE =serious adverse event ; LC/MS = liquid chromatography tandem mass spectrometry; ET = early termination.

PF-06865571
Protocol C2541007Final Protocol, 11 Dec 2020
PFIZER CONFIDENTIAL
Page 13Visit Identifier Screening Period 1 (P1) and Period 2 (P2), unless otherwise limited to 1 of these 2 PeriodsaF/U
Phone 
CallET
Days Relative to 
Day 1-42 to -2 -1 1 2 3b45 67-21c≥28 -
35
days 
(P2 
only)-
Hours After Oral
PF-06865571 Dose- - 00.5 1233.08 3.17 3.25 3.5 3.75 469121624273648 51 7296120 144-
504-
Hours After IV
[14C]PF-06865571 
Dose
(P2 Only)-3 00.08
3
(5 
min)0.17
(10 
min)0.25
(15
min)0.5
(30 
min)0.75
(45 
min)13691321243345 48
Note: Black color denotes oral dose administration and sampling post oral administration and Red color denotes IV dose administration  and sampling post IV administration. 
IV samples may optionally be labeled with the corresponding time relative to the oral dose for sample collection; however, PK da ta for the IV administration will be analyzed 
relative to the start of the IV infusion.
a. There will be a wash-out period of 8-[ADDRESS_584816] after all sample collection in Period 1 are complete.
b. In Period 2, participants will be discharged on Day 3 (ie, 48 hours IV dose administration).c. Dosing in Period 2 (as 1 cohort) or Completion of Period 1 (1 participant at a time) when at least 1 of 3 criteria are met: (1)  ≥90% of radioactive dose has been recovered in 
urine+feces+emesis (if any); (2) <1% of radioactive dose has been recovered in urine+feces during 24H interval over 2 consecuti ve days; (3) participant has reached Day 21 
(in Period 1).  At the latest, Period 2, Day -1 would occur on the same day as Period 1, Day 21.
d. Full physical examination will be conducted at Day -1 (Period 1); otherwise brief physical exam envisioned for findings durin g previous PE or new/open AEs, at 
Investigator discretion.
e. Procedures to be completed at time of discharge in Period [ADDRESS_584817] and COVID-19 related symptoms to be completed by [CONTACT_4317].
g. Participant’s body temperature will be checked at least twice daily (approximately 12 hours apart) during the CRU confinement .
h. The first body temperature check on Day 1 of each period will be performed before PF-06865571 dosing.i. Standardized meals to be served at clock times matching approximately –0.5H (see Section 5.3.1 ),andat 4H and 9-10H relative to oral PF-06865571 dosing.
k. Testing for COVID-19 pathogen (SARS-CoV-2) by [CONTACT_457933] (Screening and Admission). For par ticipants admitted for residence in 
the CRU, subsequent COVID-19 tests will be performed 2x/week at a minimum.
l. For Period 2, Plasma PK of PF-06865571 will only be assessed up to 48 hours.
m. Samples are to be collected up to 120 hours.  Based on emerging data, up to 2 additional samples for total 14C accelerator mass spectrometry (AMS) and metabolite profiling 
between Day 7 and Day 21 of Period 1 completion may be collected.
n. Sample will be used for sample dilution, if necessary, using matrix matched plasma.  [14C]PF 06865571 concentration will not be determined in this sample.
o. If not collected on the designated collection day, the banked biospecimen can be collected at the next available time point whe n biospecimens are being collected in 
conjunction with a participant visit.CCI
PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 14Visit Identifier Screening Period 1 (P1) and Period 2 (P2) , unless otherwise lim ited to 1 of these 2 PeriodsaF/U
Phone 
CallET
Days Relative to 
Day 1-42to -2 -1 1 2 3b45 67-21c≥28 -
35
days 
(P2 
only)-
Hours After Oral
PF-06865571 Dos e- - 00.5 1233.08 3.17 3.25 3.5 3.75 469121624273648 51 7296120 144-
504-
Hours After IV
[14C]PF-06865571 
Dose
(P2 Only)-3 00.08
3
(5 
min)0.17
(10 
min)0.25
(15
min)0.5
(30 
min)0.75
(45 
min)13691321243345 48
p. Microscopy required only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
q. “Blank” sample collected within 24H prior to dosing in each period; and over intervals of 0 -12H, 12 -24H, 24 -48H, 48 -72H, 72 -96H, 96-120 H plus each 24H interval , 
relative to oral dosing in Period 1. In Period 2, 
samples will be collected over 0 -12H, 12 -24H and 24-48H following administration of IVradiolabeled drug.
r. “Blank” sample collected within 24H prior to dosing in each period; samples collected over 0 -24H, 24 -48H, 48 -72H, 72-96H , 96-120 H plus each 24H interval relative to 
oral dosing in Period 1 .  In Period 2, samples will be collected over 0 -24H and 24 -48H following administration of IVradiolabeled drug.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 152.INTRODUCTION
PF-06865571 is a diacy lglycerol acyltransferase 2 (DGAT2) inhibitor that is currentl y being 
developed for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis.
2.1.Study Rationale 
The purpose of this stud y is to assess the extent of excretion of PF -06865571 as well as t he 
absolute bioavailability , fraction absorbed and pharmacokinetics of PF -06865571 in healthy  
male participants using a 14C microtracer dose approach.
2.2.Background 
Diacy lglycerol acy ltransferases (DGATs) cataly ze the terminal step in trigly ceride (TG) 
synthesis; specifically , the esterification of a fatty  acid with diacy lglycerol (DAG) resulting 
in the formation of TG.1  In mammals, two structurally  unrelated DGAT enzy mes (DGAT1 
and DGAT2) have been characterized.  DGAT1 is highl y expressed in the intestine and plays 
a central role in fat absorption.[ADDRESS_584818] s.4,5  The net result of these changes is 
a decrease in the levels of hepat
ic DAG and TG lipid which, in turn, reduces hepatocy te lipid 
burden and decreases hepatic very  low density lipoprotein (VLDL) TG secretion.5,6
PF-06865571 is a potent, reversible oral, small molecule DGAT2 inhibitor that is postulated 
to decrease hepatic TG sy nthesis and hepatic lipid burden in non -alcoholic fatty  liver disease 
(NAFLD) and nonalcoholic steatohepatitis (NASH).  Based on observations in nonclinical 
studies conducted, it is hypothesized that DGAT2i will impact both phy siological drivers 
contributing to NASH via direct inhibition of liver t riglyceride s ynthesis, as well as adaptive 
responses leading to reduction in hepatic DNL. Following 2 weeks of dosing in participants 
with NAFLD, DGAT2i has been shown to reduce liver fat in a dose- responsive manner.
2.2.1. Nonclinical Pharmacokinetics and Metab olism
Nonclinical studies indicate that PF -06865571 was rapi[INVESTIGATOR_110237] y 
absorbed in monkey  with mean oral bioavailability  of 31% and 48%, respectively . In vitro, 
PF-06865571 showed high passive permeability , and preliminary  studies indicated that 
PF-06865571 was a substrate for multi -drug resistance protein (MDR)1 (also known as 
P-glycoprotein [P -gp]) and mouse breast cancer resistance protein (mB CRP ) efflux 
transporters.
PF-[ADDRESS_584819]  identified from preliminary  in vitro and in vivo 
metabolite profiling in human is O-de-ethylation with subsequent sulfation and 
glucuronidation. There was no evidence of human unique metabolites. Reaction 
phenoty pi[INVESTIGATOR_110238] P450 (CYP) contribution to PF -06865571 
metabolism was >96%, and CYP3A was the predominant isoform responsible for the 
metabolism of PF -06865571 suggesting a risk of clinical drug -drug interactions (DDI) with 
PF-[ADDRESS_584820] that PF -06865571 has the potential to induce CYP3A4 and 
CYP2B6, in a clinical study  (C2541002), there was no dose -response relationship of 
endogenous biomarkers of CYP3A4 induction with increasing repeated doses of 
PF-06865571 up to 1800 mg/day . PF-06865571 also has the potential to inhibit uridine 
diphosphate -glucuronos ytransferase (UGT) 1A1, UGT1A9, and UGT2B15 based on in vitro 
data from human liver microsomes. In addition, in vitro evaluations suggest that 
PF-[ADDRESS_584821] cancer 
resistance protein (BCRP), organic cation transporter (OCT)1, OCT2, and multidrug and 
toxic compound extrusion transporter (MATE)[ADDRESS_584822] (ie, 300 mg twice dail y [BID]).
2.2.2. Clinical Overview
[IP_ADDRESS]. Summary of Clinical Safety
As of the issuance of this protocol, 9clinical studie s with PF -[ADDRESS_584823] been randomized. 
This includes 141 unique healthy adult participants, 18 adults with hepatic impairment, and 
165 adults with NAFLD. Of the 306 particip ants randomized, 231 (75%) were exposed to 
PF-06865571 - 65 unique participants (28%) to single oral doses of PF 06865571 and an 
additional 166 participants (72%) to repeated, oral, doses of PF -06865571 for up to 6 weeks.
Administration of PF -06865571 alon e has been found to be well tolerated with the maximum 
tolerated dose not identified and no adverse drug reactions identified.  Upon administration 
of single oral doses of PF -06865571, across the 300-fold dose range evalua ted (ie, 5 to 1500 
mg), TEAEs repo rted in ≥ 4 participants across all arms evaluated were headache (12%), and 
diarrhea (7%).
[IP_ADDRESS]. Summary of Clinical Pharmacology
Following administration of single oral doses of PF- 06865571 under fed conditions in 
C2541001, median time for C max(Tmax) ranged fro m 1.5 to 4 hours across the dose groups.  
Approximate dose -proportional increases in C maxand AUC 24were observed between the 
5mg and 1500 mg doses.  Under fed conditions, the mean terminal elimination half -life (t ½) 
ranged from 1.5 to 5.2 hours.  At the 1000 mg dose level, exposures under fasted condition 
were approximately  2-fold lower than those in the fed state.  Median PF- 06865571 T max
occurred earlier in the fasted state, compared to dosing under fed conditions (1 h versus 4 h).  
In addition, the ter minal elimination t ½under fasted conditions was more variable than under 
fed conditions.   

PF-[ADDRESS_584824] 
been reached b y Da y 4 based on PF -06865571 median trough plasma concentration- time 
profiles. Following a single dose on Day  1 and at steady  state (Day s 7 and 14), PF -06865571 
plasma exposure across the 30 mg - 600 mg Q8H doses appeared to increase in a dose 
proportional manner based on geometric mean AUC tauand Cmaxvalues. Mean t½on Day  14 
ranged from 3.29 hours to 6.92 hours across the 30 mg - 600 m g Q8H doses with longer t½
values observed at higher doses. Minimum drug accumulation was observed following 
multiple dose administration of PF -06865571 Q8H.  Mean accumulation ratios ranged from 
0.950 to 1.33 based on AUC tauvalues and 0.990 to 1.44 base d on C maxvalues across all doses 
on both Day  7 and Day  14. The proportion of drug excreted via renal elimination on Day  14 
was low, with less than approximately 2% (mean Ae tau% values ranged between 0.696% and 
1.79%) of the dose excreted in urine as unchanged drug over the dosing interval across the 
30mg -600 mg Q8H doses.  Mean CLr values ranged between 0.293 to 0.630 L /hr.
2.3.Benefit/Risk Assessment
The current study  is the first to administer radiolabeled, nCi doses of [14C ]PF-06865571 –
both orally  and intravenously . The single doses of PF -[ADDRESS_584825] been identified with oral 
administration of PF -06865571; potential risks wit h PF-[ZIP_CODE] 571 and the current study , are 
summarized in Section 2.3.1.  More detailed information about the known and expected 
benefits and risks and reasonably  expected adverse events of PF-
06865571 may be found in 
the investigator’s brochure, which is the SRSD for this study . 

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 182.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Stra tegy
Study Intervention(s) PF-[ADDRESS_584826] time clinical administration of 
[14C]PF -06865571 –both orally and 
intravenouslySingle oral doses up to 1500 mg of PF -
06865571 observed to be w ell tolerated; single, 
oral dose of PF -06865571 in this study (300 mg) 
represents is 5 -fold lower
IV dose of PF -06865571 in this study (100 µg) 
is 15,[ADDRESS_584827] oral dose 
previously administered and observed to be w ell 
tolerated
Micro tracer of [14C]PF -06865571 identified for 
this study (300 nCi) is equivalent to 0.75 mrem ,
which represent sradiation exposure which is 
well below the average dose (in US) per year 
from background radiation sources which is 610 
mrem ,and below  common acute radiation doses 
(eg,Dental x -ray ~ 1.5 mrem; Transatlantic 
flight ~ 2.5 mrem; Mammogram ~ 72 mrem; 
Full body CT scan ~ 1000 mrem) .Additionally, 
the radioactive dose to be administered is 
categorized as the lowest risk category of 1 by 
[CONTACT_457934].7Administration of PF -06865571 will occur in an 
inpatient setting under close supervision
Clear communication via ICD of negligible risk 
with the [14C]PF -[ADDRESS_584828] oral doseClinical data indicate that PF -06865571 
exposure are low er in fasted state than in fed 
stateStudy intervention, when administered orally, 
administered with a meal
Exposure in utero In embryo -fetal developmen t toxicity study in 
rats, low er fetal body weight and skeletal 
anomalies observed at all doses with NOAEL for 
this developmental toxicity not identified
In embryo -fetal developmental toxicity study in 
rabbits , no developmental toxicity observedRisk of fetal toxicity communicated through 
Section 7 of the PF -06865571 IB (Jan -2020)
Enrollment in this study, con sidering 
administration of [14C]-study intervention, 
limited to healthy adult males
In males who are sexually active with female 
partner(s) of childbearing potential, use of 
barrier methods not required/mandated given 
safety margins >100 -fold –refer to Se ction 10.4

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 19Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Stra tegy
Study Procedures 
Number of serial andparallel procedures to 
ensure near complete collection of each 
radioactive dose administered carry risks for 
non-evaluable dataDuration of washout between the 2 Periods in 
this study are pre -defined but rather guided by 
[CONTACT_457935], urine, 
feces, and when applicable vomitus –which will 
likely vary between participantsFeasibility of paral lel evaluation of PK, 
radioactivity, safety is precedented at site 
selected for this study
A priori identified criteria for when dosing can 
occur in Period 2 outlined in Schedule of 
Activ ities
Clear communication in protocol and to 
participants ( via ICD )about the maximum
possible duration of inpatient stay with this stay 
reduced as guided by [CONTACT_457936]- 19 contamination during study During the pandemic healthy participant could 
be infected with the SARS -COV -2 virus 
through study participation
Leading to increased health risk for study
participant sand others involved in study 
conduct, potentially confounding AE with study 
interventionCOVID -19 specific assessments according to 
Schedule of Activ ities

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 202.3.2. Benefit Assessment
The participants inthis study are not expected to obtain any  specific benefit beyond 
contributing to the process of developi[INVESTIGATOR_336243]. They  will 
receive close monitoring of their safety  via study  procedures undertaken (eg, PE, 12 -lead 
ECGs, vital signs) which will
occur as outlined in this protocol.
2.3.3. Overall Benefit /Risk Conclusion
Based on the safety  profile of PF -06865571 observed in clinical studies to date, and the 
measures taken as part of the study  designed outlined in this protocol, the risk to the 
participants in this study  is deemed to be mi nimal. The overall benefit:risk profile for 
PF-[ADDRESS_584829] of this study .
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Primary: Primary: 
 To characterize the extent of excretion of total 
radioactivity in urine and feces following 
administration of a single oral dose of 
[14C]PF-06865571 . Total recovery of radioactivity in urine, feces and total 
excreta (urine + feces) as percentage of total 
radioactive dose administered.
 To characterize the metabolic profile and identify 
circulating and excreted metabolites following 
administration of a single oral dose of 
[14C]PF-06865571 . Metabolic profiling/identification and determination 
of relative abundance of [14C]PF -06865571 and the 
metabolites of [14C]PF-06865571 in plasma, urine and 
feces.
Secondary: Secondary: 
 To quantify plasma PK parameters of PF-06865571
and total radioactivity following administration of a 
single oral dose of [14C]PF-06865571 .   Period 1: AUC last, Cmax, Tmax, and if data permit,
AUC infandt½to describe single oral dose of:
 Total radioactivity in plasma
 PF-06865571 in plasma
 To quantify plasma PK parameters of PF-06865571
following administration of a single, IV, microtracer 
of[14C]PF-06865571 . [14C]PF-06865571 (Period 2 ): AUC last, Cmax, Tmax,and 
if data permit, t ½, AUC inf, CL and V ss.
 To determine the absolute oral bioavailability ( F)of 
PF-06865571 following administration of a single 
oral dose of PF-06865571 compared to a single IV 
microtracer of [14C]PF -06865571 .  Plasma AUC infoforal unlabeled PF-06865571 and 
IV microtracer of [14C]PF-06865571 in Period 2 only.
 To determine the fraction of the dose absorbed ( Fa)
following administration of a single oral dose of 
[14C]PF-06865571 . Total urinary radioactivity following oral 
administration of [14C]PF-06865571 in Period 1 and 
IV microtracer administration of [14C]PF -06865571 in 
Period 2 .
Tertiary/Exploratory: Tertiary/Exploratory: 
 To characterize cumulative rate of excretion of total 
radioactivity in urine and feces over time following 
administration of a single oral dose of 
[14C]PF ‑06865571 . Cumulative recovery of radioactivity in urine and 
feces, and total excreta (urine + feces) over time as a 
percentage of total radioactive dose a dministered .

PF-06865571
Protocol C2541007Final Protocol, 11 Dec 2020
PFIZER CONFIDENTIAL
Page 21Objectives Endpoints
• To quantify plasma PK parameters of PF-06865571 
in plasma following administration of a single oral dose of unlabeled PF-06865571.• PF-06865571 plasma (Period 2): AUC
last, Cmax, Tmax, 
and if data permit, t ½, AUC inf, CL/F, V z/F.
 
  
 
• To evaluate the safety and tolerability of PF-
06865571, administered as a single oral dose of 
[14C]PF-06865571 or a single oral dose of 
PF-06865571 followed by [CONTACT_17814] a single IV microtracer of [
14C]PF-06865571.• AE monitoring, clinical laboratory measurements, 
vital signs and 12-lead ECG.
4. STUDY DESIGN
4.1. Overall DesignThis study is a Phase 1, open-label, non-randomized, 2-period, fixed-sequence, single-dose 
study of PF-06865571 in healthy male participants to characterize the ADME properties of[
14C]PF-06865571 following oral administration; and to evaluate the absolute oral 
bioavailability (F) and fraction absorbed (Fa) of PF-06865571 following oral administration of unlabeled PF-06865571 and IV administration of [
14C]PF-06865571.  
In this study [ADDRESS_584830] 4 
participants.  Each participant will receive 2 regimens (A and B) in Periods 1 and 2, respectively, as outlined in Figure 1.  Participants who withdraw from the study may be replaced if the number of evaluable participants is less than 4.
Figure 1. Two (2)-Period Fixed Sequence Study Design
*
Completion of Period 1 (1 participant at a time) when at least 1 of 3 criteria are met: (1) ≥90% of radioactive 
dose has been recovered in urine+feces+emesis (if any); (2) <1% of radioactive dose has been recovered in 
urine+feces during 24H interval over 2 consecutive days; (3) participant has reached Day 21 (in Period 1).
At the latest, Period 2, Day -1 would occur on the same day as Period 1, Day 21.Washout (8 to 22 days)
\\
Period 1
300 nCi/300 mg PO
Period 2300 mg PO followed by 
300 nCi/100 μg IV at 
~[ADDRESS_584831] oral dose
Dosing
(D1)Dosing
(D1)
Plasma, Urine & Feces
(vomitus, as applicable)
Collection in Period 1Plasma, Urine & Feces
Collection in Period 2Follow up 
(≥28 to 35 days after 
dosing in Period 2)Completion of 
Period 1 (D7-21)*Discharge 
from CRU (D3)CCI
PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 22Regimen A in Period 1: An oral dose of 300 mg PF- 06865571 containing approximately  
300nCi 14C (ie, radiolabeled PF -06865571) will be administered within approximately  [ADDRESS_584832] (see Section s 5.3.1 and 6.1.1).
Regimen B in Period 2: An oral dose of 300 mg unlabeled PF- 06865571 followed at T maxby 
[CONTACT_457937] 300 nCi [14C]in 100 g of PF-06865571 (3Ci/mg active drug).  The [14C ] IV 
dose will be administered as an infusion over approximately  15minutes.  Oral unlabeled PF-
[ADDRESS_584833] (see Sections 5.3.1 and 6.1.1).
Screening will occur within 
42days of the first dose of the investigational product in 
Period 1.  All participants will provide informed consent and undergo screening evaluations 
to determine their eligibility . 
Eligible participants will be admitted to the CRU on Day  -1 of Period 1 and scheduled to 
remain in the CRU through the completion of Period 2
.  As such, inpatient stay  will be for a 
total duration of 12 days (minimum) to 25 day s (maximum ) .  Each participant will have 
[ADDRESS_584834] the CRU for personal reasons, at the discretion 
of the investigator, for up to a maximum of 8 hours during Period 1 after Day  7, if the 
participant has completed Period 1 based on the completion criteria defined in Figure 1.  
4.2.Scientific Rationale for Study Design
This study  will investigate the ADME of [14C]PF-
06865571 and characterize plasma, fecal
and urinary  radioactivit y and identify  any metabolites, if possible, of [14C]PF-06865571 in
male participants (obtained from Periods 1 and 2).  A 2-period design is being used to 
minimize variability  and enable within - participant comparison of the urinary  excretion of 
radioactivity  with both routes for the estimation of F a.  Onl y male participants will be 
enrolled toalso minimize variability . Only nonsmoker swill be enrolled to minimize any  
potential effect on metabolism b y smoking. In addition, this study  will provide a better 
understanding of the PK disposition of PF -06865571 by [CONTACT_457938] (F and Fa), further assisting with BCS class ification
assessment 
for PF-06865571 . This information will support the further formulation 
development.   Oral dosing will be administered with a meal as food has been shown to 
significantl yincrease exposures of 
PF-06865571 and mimics how PF-06865571 is being 
administered in the clinical program.
Period 2 of this study  will enable assessment of F for PF-06865571.  F will provide 
information on the amount of PF-
06865571 reaching the s ystemic circulation.  Determination 
of the Fa (obtained from Periods 1 and 2) will provide information on the fraction of the total 
PF-06865571 dose absorbed, regardless of the fate of that dose after absorption (ie,
metabolism, degradation, etc).  Since F is dependent on Fa, Fg and Fh, characterization of 

PF-[ADDRESS_584835]. Therefore, the study will aim 
to characterize both F and Fa.
In order to achieve sufficient bioanalytical sensitivity for the microtracer dose and
differentiate the plasma concentrations resulting from the radiolabeled IV dose and thoseresulting from the oral dose, an ultra-sensitive AMS method will be used to quantify plasma concentrations of radiolabeled parent drug as well as total
14C derived from the microtracer 
dose based on measurement of 14C.8  PF-06865571 will be considered highly permeable if 
either F or Fa is greater than 0.85 (as per BCS guidance).9
 
The potential risk of exposure to PF-06865571 in a sexual partner of a male participant in 
this study via ejaculate is low, and therefore no contraception (condom) use in male 
participants is warranted.  The calculated safety margin is ≥100-fold between the estimated 
partner exposure due to seminal transfer and the NOAEL for serious manifestations of developmental toxicity in nonclinical studies.  The safety margin of 100-fold is based on applying a 10-fold safety factor for interspecies extrapolation and a 10-fold safety factor for susceptible populations.
10
Banked Biospecimens will be collected and stored for further analyses which may, for example, provide greater understanding of the study intervention.
4.3. Justification for Dose
•
14C-labeled PF-06865571 and unlabeled Oral PF-06865571:
A radio-dilute 14C-labeled (300 nCi) [ADDRESS_584836] dose being evaluated in phase 2 clinical program.  PF-06865571 was found to be well-tolerated with anacceptable safety profile with single doses up to 1500 mg (C2541001) and repeated doses up to 1800 mg/day (C2541002) in healthy participants.  A maximum tolerated dose was not identified.  In addition, 300 mg BID dose levels were found to be generally well tolerated with an acceptable safety profile over 6-week treatment in NAFLD patients (C3711001).Based on prior experience in healthy participants and NAFLD patients, a single [ADDRESS_584837] low risk into healthy adult males (see Section 2.2.2 ). 
Further, single-dose administration is chosen because linear and time-independent PK of   
PF-[ADDRESS_584838] multiple-dose PK of PF-06865571.
•
14C-labeled PF-06865571 IV microtracer:
The microtracer selection is based on ICH Guidelines.11  A microtracer [14C]PF-06865571 is CCI
PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 24planned in this study for both oral (Period 1; 0.001 μCi/mg active dose or 300 nCi/300 mg 
active dose) and IV (Period 2; 3 μCi/mg active dose or 300 nCi/100 μg active dose) 
administration.  The total radioactive dose would be approximately  600 nCi of 14C.  The I V 
dose of 100 gis 0.033% of the oral unlabeled dose of 300 mg.  This dose is sufficient to 
allow quantification of [14C]PF-
[ADDRESS_584839] scheduled procedure shown in the Schedule of Activ ities(ie,follow -
up phone call) .
The end of the stud y is defined as the date of the last scheduled procedure shown in the 
Schedule of Activ itiesfor the last participant in the trial.
5. STUDY POPULATION
This study  can fulfill its objectives only if appropriate participant s are enrolled.  The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate.  All relevant medical and nonmedical conditions should be 
taken into cons
ideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1.Male participant s, 18 to 60years of age ,inclusive, at the time of signing the ICD.
Refer to Appendix 4forreprod uctive criteria for male participant s 
(Section 10.4.1).
Type of Participant and Disease Characteristics:
2.Male p
articipants who are overtl y health y as determined by [CONTACT_394984], phy sical examination, laboratory  tests, and cardiac tests.
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
4.Participants that are non smoking for at least 3 months at the time of signing the ICD.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 25Weight:
5.BMI of 17.5 to 30 .4kg/m2, inclusive ;and a total body  weight >50 kg (110 lb)with a 
single repeat assessment of BMI and/or bod y weight permitted on a different day to 
assess eligibility , if needed .
Informed Consent:
6. Capable of giving signed informed consent as described in Appendix 1, which 
includes compliance with the requirements and restrictions listed in the I CD and in 
this protocol.
5.2.Exclusion Criteri a
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurolo gical, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing ).
2.Any condition possibly  affecting drug absorption (eg, gastrectomy , cholecy stectom y).
3.History  of irregular bowel movements including irritable bowel s yndrome or frequent
epi[INVESTIGATOR_457921] ,defined by  [CONTACT_21316] 1 bowel movement on 
average per 2 day s, or lactose intolerance.
4.History  of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, 
or HCVAb. Hepatitis B vaccination is allowed.
5.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation /behavior or laboratory  abnormality  or other conditions or 
situations related to the COVID -
19 pandemic that may  increase the risk ofstudy  
participation or , in the investigator’s judgment, make the participant inappropriate for 
thestudy .
History  of SARS -CoV -2 PCR or antibody  (eg,IgG, IgM, etc) 
positive result 
would necessitate accompany ing history  of as ymptomatic state for at least 6 
months prior to screening. 
Prior/Concomitant Therapy:
6.Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention with the exception of moderate/potent CYP3A inducers which are 

PF-[ADDRESS_584840] dose of stud y intervention.  
(Refer to Section 6.5for additional details).
Prior/Concurrent Clinical Study Experience:
7.Previous administration with an investigational drug within 60days (or as determined 
by [CONTACT_19970]) preceding the first dose of study  intervention used in this 
study (whichever is longer). 
Diagnostic Assessments:
8.A positive urine drug test .
9.A positive urine cotinine test.
10.Screening supi[INVESTIGATOR_30991] ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least 5 minutes of supi[INVESTIGATOR_457922] t.  If BP is ≥ 140mmHg (sy stolic) or ≥90 mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant ’s eligibility .
11.Baseline 12-lead ECG thatdemonstrates clinically relevant abn ormalities thatmay
affect participant safety or interpretation of study results (eg, baseline QTc Finterval
>[ADDRESS_584841]- degree AVblock, or serious brady arrhy thmias or tachy arrhy thmias). If QTc F
exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more 
times and the average of the 3 QTc or QRS values should be used to determine the 
participant’s eligibility .  Computer -interpreted ECGs should be overread b y a 
physician experienced in reading ECGs before excluding participant s
.
12.Participant s with ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary :
AST or ALT level ≥ 1.5 × ULN;
Total bilirubin level ≥ 1.5 × ULN; participants with a history of Gilbert's 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is≤ ULN.
13.A positive COVID -
19(SARS -CoV -2)PCR test.
Other Exclusions:
14.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening.  Bing e drinking is defined as a pattern of 5 

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 27or more alcoholic drinks in about 2 hours .  As a general rule, alcohol intake should 
not exceed 14units per week (1 unit=
8ounces (240 mL) beer, 1 ounce (30 mL) of 
40% spi[INVESTIGATOR_107060] 3 ounces (90 mL) of wine).
15.Total 14C radioactivity  measured in plasma exceeding 11 mBq/mL at screening .
16.From 3 months prior to dosing use of tobacco/nicotine containing products or positive 
urine cotinine test.
17.Blood donation (excluding plasma donations) of approximately  1pi[INVESTIGATOR_11731] (500 mL)or 
more within 60days prior to dosing . 
18.History  of sensitivity  to heparin or heparin -induced thrombocy topenia only if heparin 
is used to flush I V catheters used during serial blood collections . 
19.Unwilling or unable to comply  with the lifest yle considerat ions outlined in 
Section
5.3of this protocol.
20.Investigator site staff or [COMPANY_007] employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised b y the investigator, and their respective family 
members.
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1.
Meals and Dietary Restrictions
After confirmation of eligibility , participant s must be reminded that they  must :
attempt to abstain from ingestion of indigestible foods (eg, corn, nuts) for 2 days prior 
to dosing (ie, Day  -2 and Day  -1);
In addition, while inpatient, the meals consumed will follow this restriction to aid 
fecal homogenization. 
refrain from consuming red wine, g rapefruit ,or grapefruit -related citrus fruits /fruit 
juices (eg, Seville oranges, pomelos) from [ADDRESS_584842] dose of study  
intervention until collection of the final PK blood sample
, in each Period.
While inpatient, the meals consumed are expe cted to follow the restrictions outlined below 
with participant s encouraged to complete each meal. 
Participant s must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations.
Water is permitted until dosing on Day  1 and without restriction beginning 1 hour 
after oral dosing.  

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 28Noncaffeinated drinks (except grapefruit or grapefruit -related citrus fruit juices—see 
below) may  be consumed with meals and the evening snack.
While inpatient , meals will be standardized as follows –
On Day  [ADDRESS_584843].
The percentage of the meal 
consumed should be documented.
Lunch will be provided approximately  4hours after dosing of oral PF- 06865571 .
Dinner will be provided approximately  9to 10 hours after dosing of oral 
PF-06865571.
An evening snack ispermitted .
Standard meal s(and an optional evening snack) will be provided at a similar 
clock time to the clock time when these meals are offered on Day  1.
While participants are confined, their total daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein.  The dail y caloric 
intake per participant should not exceed approximately  3200 kcal.
To help assure regularit y in bowel movements, nutritional composi tion should 
contain at least 15 g of fiber per 1000 kcal
This may  include consumption of fiber capsules, at a frequency  dictated by  
[CONTACT_1697], starting with the evening meal (ie, ~ 8H post dose) on Day  1, for 
duration of inpatient stay to ensure at least one bowel movement per day ; 
If an individual participant has not experienced a bowel m ovement in the first 24 
hours after dosing, fluid intake should be increased and administration of a mild 
laxative [eg, prune juice or a mild stool softener (eg, docusate)] should be 
implemented, with the goal to facilitate at least one daily  bowel movement ; 
Despi[INVESTIGATOR_37104], if bowel movement does not occur, on Day  2 and 
each subsequent day , consideration should be given to administration of mild 
laxative (eg, milk of magnesia), at the Investigator’s discretion. The use of the 
stool softener / laxative needs to be recorded.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 295.3.2. Caffeine, Alcohol, and Tobacco
Participant s will abstain from caffeine -containing products for 24 hours prior to the 
start of dosing until collection of the final PK blood sample in each Period.  
Participant s will abstain from alcohol for 24 hours prior (or as specified above for red 
wine) to admission to the CRU and continue abstaining from alcohol until collection 
of the final PK blood sample ineach Period.  Participant s may  undergo an alcohol 
breath test or urine alcohol test at the discretion of the investigator.
Participant s will abstain from the use of tobacco -or nicotine -containing products
from [ADDRESS_584844] at the discretion of the investigator.
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to admission and while confined to 
the CRU in the study .  Wal king at a normal pace will be permitted;
In order to standardize the conditions on PKsampling day s, participant s will be 
required to refrain from ly ing down (except when required for BP, pulse rate , and 
ECG measurements), eating, and drinking beverages ot her than water during the first 
4
hours after dosing;
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study . Screen failure data are collected and remain as 
source and are not reported to the clinical database.
Individuals who do not meet the criteria for participation in this study  (screen failure) cannot
be rescreened. 
6. STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, the term investig ational product may  be used 
synony mously  with study  intervention.
6.1. Study Intervention(s) Administered
Unlabeled (ie, non -radiolabeled) PF-[ADDRESS_584845] for oral administration 
will be supplied to the CRU by [CONTACT_457939].

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 30Two (2) batches of GMP [14C]PF-06865571 API [INVESTIGATOR_457923] y 
radio -diluted to the overall specific activity  requirements for 
Period 1 oral dosing and the 
other API [INVESTIGATOR_457924] y for IV formulation for Period 2 IV dosing. 
[14C]PF-06865571 components for the IV and oral microtracer administration will be 
supplied by  [CONTACT_457940] [INVESTIGATOR_1238], where necessary , bulk excipi[INVESTIGATOR_457925] [14C] labeled I Vsolution and oral suspension formulations. Thefinal product 
composition and presentation will be detailed in a separate Technical Agreement ( TA)for the 
[14C] labeled I V solution and Extemporaneous Dispensing Record s (EDR s)for the [14C] 
labeled and unlabeled oral suspensions.
6.1.1. Administration
In Period 1, [14C]PF- 06865571 will be administered as an oral dose. In Period 2, the oral 
unlabeled PF-
06865571 will be administered 3hoursbefore the IV [14C]PF-06865571 dose. 
14C labeled or unlabeled PF-06865571 (300 mg):Astandard meal will be provided 
approximately  [ADDRESS_584846]
igator site personnel will 
administer labeled or unlabeled PF-06865571 via oral route at approximately  0800 hours 
(plus or minus 2 hours) within approximately  10 minutes of completion of the meal during 
the designated period with water to a total volume of 240 mLaccording to the site 
administration instructions.
[14C]PF -06865571 (100g): Ten mL of the 10 g/mL manufactured IV solution of [14C]PF -
06865571 will be administered intravenousl y (over 15 minutes as a continuous infusion 
through an infusion lineusing a  calibrated s yringe pump or similar ).  Preparation and 
administration of [14C]PF -06865571 will be performed by  [CONTACT_457941] (in accordance with local regulations and laws).  Further details on administration 
are outlin ed in the site administration instructions . 
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepan cies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention.   All study 
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  At a 
minimum, daily  minimum and maximum tempe ratures for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indicate the minimum and maximum temperature ssince previousl y documented for 
all site storage locations upon return to business.

PF-[ADDRESS_584847] /Roles and Responsibility  Matrix .
4.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_78254].
5.Study  interventions should be s
tored in their original containers.
6.See the EDR for storage conditions of the study  intervention once reconstituted 
and/or diluted.
7.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability , reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention s
will be accounted for 
using a study  intervention accountabilit y form/record.
8.Further guidance and information for the final disposition of unused study  
interventions are provided in the Roles and Responsibility  Matrix .  All destruction 
must be adequatel y documented.  If destruction is authorized to take pla ce at the 
investigator site, the investigator must ensure that the materials are destro yed in 
compliance with applicable environmental regulations, institutional policy , and any  
special instructions provided by  [CONTACT_4618].
Upon identification of a product comp laint, notify the sponsor w ithin 1 business day  of 
discovery .
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the 
study  intervention ready  for administration or dispensing to the participant by [CONTACT_216479].  Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider, 
participant in accordance with this protocol.  L ocal hea lth authority  regulations or 
investigator site guidelines may  use alternative terms for these activities.
14C labeled and unlabeled PF-[ADDRESS_584848] .  
Details of dose preparations will be given in separate EDRs.  Prepared doses will be provided 
in unit dose containers and labeled in accordance with [COMPANY_007] regulations and the investigator 
site’s labeling requirements.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 32[14C]PF-06865571 so lution for the IV administration will be manufactured at the clinical 
study  site by  2 trained personnel and qualit y assurance (QA) released prior to administration.  
Details of the dose preparation will be provided in a separate TA.  Prepared doses will be
provided in unit dose containers and labeled in accordance with [COMPANY_007] regulations and the 
investigator site’s labeling requirements.   Leftover containers following both oral and IV 
administration, including tubing used for infusion, should be shipped to laboratory  for 
assessment of radioactivity , if needed. 
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular 
participan t or affect the order in which participant s are enrolled.
Following completion of informed consent at the Screening visit, each participant will be 
assigned a single [ADDRESS_584849] each 
participant’s unique number assigned in chronological order of when informed consent is 
obtained.  Separately , prior to dosing on Day 1, each participant will be as signed a 2- digit 
number to permit anal ysis of all PK samples.
6.4. Study Intervention Compliance
When the individual dose for a participant is prepared from a bulk supply, the preparation of 
the dose will be confirmed by  a second qualified member of the study  site staff.
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents and rec orded in the CRF.  
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention.
The site will complete the requ ired dosage Preparation Record located in the EDR .  The use 
of the Preparation Record is preferred ,but it does not preclude the use of an existing 
appropriate clinical site documentation sy stem.  The existing clinical site's documentation 
system should ca pture all pertinent/required information on the preparation and 
administration of the dose.  This may  be used in place of the Preparation Record after 
approval from the sponsor and/or designee.
6.5. Concomitant Therapy
Use of prescription or nonprescription dru gs and dietary and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention with the exception of moderate/potent CYP3A inducers which are prohibited 
within [ADDRESS_584850] participant safety  or the overall 

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 33results of the study  may  be permitted on a case-by-case basis following approval by  [CONTACT_103] .Acetaminophen /paracetamol may be used at doses of ≤1g/day .  If an individual 
participant has not experienced a bowel movement within 24 hours after dosing of oral 
(Period 1) or IV (Period 2) 
[14C]PF-06865571, administration of a mild laxative [eg, prune 
juice or a mild stool softener (eg, docusate) ] should be implemented, with the goal to 
facilitate at least one daily  bowel movement.  Despi[INVESTIGATOR_37104], if bowel movement 
does not occur, on Day  2and each subsequent day, consideration should be given to 
administration of mild laxative (eg, milk of magnesia), at the Investigator’s discretion .  The 
use of the stool softener / laxative should be recorded.
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and s tart and stop dates of administration.  All participant s will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within 
42days before the first dose of study  intervention will be 
documented as a prior treatment.  Treatments t aken after the first dose of study  intervention
will be documented as concomitant treatments.
6.5.1. Rescue Medic ine
There is no rescue therapy to reverse the AEs observed with PF-06865571; standard medical 
supportive care must be provided to manage the AEs. 
6.6.
Dose Modification
Not applicable.
6.7.Intervention A fter the End of the Study
No intervention will be provided to study participants at the end of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of S tudy Intervention
In rare instances, it may  be necessary  for a participant to permanentl y discontinue study  
intervention (definitive discontinuation) .Reasons for definitive discontinuation of study  
intervention include the following :intolerance of the study  drug, SAE, clinically  relevant 
laboratory , vital signs or ECG changes
.
If study  intervention is definitively  discontinued, the participant will not remain in the study  
for further evalu ation. See the Schedule of Activ itiesfor data to be collected at the time of 
discontinuation of study  intervention.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 347.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request .  Reasons for 
discontinuation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death ;
Study  terminated by  [CONTACT_3211] ;
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
beconducted .See theSchedule of Activ itiesfor assessments to be collected at the time of 
study  discontinuation and follow -up and for an y further evaluations that need to be 
completed. 
The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .  Participants should be questioned regarding 
their reason for withdrawal.
  
If a participant withdraws from the stud y, he/she may  request destruction of any  remaining 
samples taken and not tested, and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdra wsconsent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected.  The spons or may  retain and continue to use any  data 
collected before such withdrawal of consent.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preser ved.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures.  The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_78258].  Participant s should notify  the investigator in writing of the decision to 
withdraw consent from future follow -up, whenever possible.  The withdrawal of consent 
should be explained in detail in the medical records by  [CONTACT_093], as to whether the 
withdrawal is only  from further receipt of study  intervention or also from study  procedures 
and/or posttre atment study  follow -up, and entered on the appropriate CRF page.  In the event 
that vital status (whether the participant is alive or dead) is being measured, publicly  

PF-[ADDRESS_584851] be taken if a participant fails to attend a required study  visit:
The site must attempt to contact [CONTACT_288949]/or 
should continue in the study ;
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls a nd, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record ;
Should the participant continue to be unreachable, he/she w ill be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedu res and their timing are summarized in the Schedule of Activ ities. Protocol
waivers or exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or dis
continue study  
intervention.
Adherence to the stud y design requirements, including those specified in the Schedule of 
Activi ties, is essential and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Participant s will be screened within 42 days prior to administration of the study  intervention
to confirm that they  meet the study  population criteria for the study .  If the time between 
screening and dosing exceeds 42 days as a result of unexpected delay s (eg, delay ed drug 

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 36shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
A participant who qualified for this protocol but did not enroll f roman earlier cohort /group
may be used in a subsequent cohort /group withoutrescreening ,provided laboratory  results 
obtained prior to the first dose administration meet eligibility  criteria for this study .  In 
addit ion, other clinical assessments or specimen collections, eg, banked biospecimens, may  
be used without repeat collection, as appropriate.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant.  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.
Ifan IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate andBP) should be collected prior 
to the insertion of the cathe ter.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood sampling volume for indivi dual participant s in this study  is approximately  
415mL.  The actual collection times of blood sampling may  change.  Additional blood 
samples may  be taken for safet y assessments at times specified b y [COMPANY_007], provided the total 
volume taken during the study does not exceed 550 mLduring any period of 60 consecutive 
days.
8.1.Efficacy Assessments
There are no efficacy  assessments included in this protocol .
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the Schedule of Activ ities.  
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues
.
8.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 37A brief physical examination will include, at a minimum, assessments of general app earance, 
the respi[INVESTIGATOR_2866] s ystems, and participant -reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per theSchedule of Activ ities.  For 
measuring weight, a scale with appropriate range and resolution is used and must be placed 
on a stable, f lat surface. Participant s must remove shoes, bulky  layers of clothing, and 
jackets s othat only  light clothing remains.  They  must also remove the contents of their 
pockets and remain still during measurement of weight. 
8.2.2. Vital Signs
Supi[INVESTIGATOR_394979] ’s arm supported at the level of the heart, and 
recorded to the nearest mm Hgafter approximately  5minutes of rest .  The same arm 
(preferabl y the dominant arm) will be used throughout the study .  BP should not be taken 
from the ar m with a catheter in place for intravenous infusion.
  Participant s should be 
instructed not to speak during measurements .  
The same properl y sized and calibrated BP cuff will be used to measure BP each time.  The 
use of an automated device for measuring B P and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds.  When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained p
rior to the nominal time of the blood collection (and prior 
to collection of ECG) .
Additional collection times, or changes to collection times, of BPand pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety  data.
8.2.3. Electrocardiograms
Standard 12-l ead E CGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the S chedule of Activi tiessection of this protocol using an 
ECG machine that automatically  calculates the heart rate and measures PR, QT, and QTcF
intervals and QRS complex .Alternative lead placement methodology using torso leads (eg ,
Mason- Likar) is not recommended given the potential risk of discrepancies with ECGs 
acquired using standard limb lead placement. All scheduled ECGs should be performed after 
the participant has rested quietly  for at least 10 minutes in a supi[INVESTIGATOR_2547]. 
To ensure safet y of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements.  Additional ECG monitoring will occur if a) a 
postdose QTc Finterval is increased by  ≥60 msecfrom the baseline andis >45 0msec; or b) 
an absolute QTc Fvalue is ≥[ADDRESS_584852] hourly  until QTc F

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 38values from 2 successive ECGs fall below the threshold value that triggered the repeat 
measurement.
If a) a postdose QTc Finterval remains ≥60msecfrom the baseline andis >450 msec; or b) 
an absolute QTc Fvalue is ≥500 msecfor an y scheduled ECG for greater than 4 hours (or 
sooner , at the discretion of the investigator); or c) QTcFintervals get progressively longer, 
the participant should underg o continuous ECG monitoring.  
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings.  If a machine- read QTc
or QTcF value sareprolonged, as defined above, repeat measurements may not be necessary  
if a qualified medical provider ’s interpretation determines that the QTc and QTcF values are 
in the acceptable range.
Additional collection times, or changes to collection times, of ECG will be permitted, as 
necessary , to ensure appropriate collection of safety  data.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.4. Clinical Safety Laboratory Assessments
SeeAppendix [ADDRESS_584853] an y 
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_584854] dose of study intervention
should be 
repeated until the values return to normal or baseline or are no longer considered 
clinically  significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
SeeAppendix 6for suggested actions and follow -up assessments in the event of potential 
drug-induced liver injury.

PF-[ADDRESS_584855] igator.
In addition, as per local practices , site -generated COVID -19 Questionnaire will be expected 
to be completed b
y the participants each time upon arrival to the clinic –refer to Schedule of 
Activi ties.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3.
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events th at meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
t
hestudy  intervention (seeSection 7.1). 
Each participant will be questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow - up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study intervention ), through and including a 
minimum of 28calendar days after the last administration of the study intervention .
Follow -up by  [CONTACT_340757] a level acceptable to the 
investigator and [COMPANY_007] concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.

PF-[ADDRESS_584856] SAE Report Form.
Investigators are not obligated to activel y seek AE or SAE after the participant has concluded 
study  participation . However, if the investigator l earns of any SAE, including a death, at an y 
time after a participant has completed the study , and he/she considers the event to be 
reasonabl y related to the study  intervention, the investigator must promptl y report the SAE to 
[COMPANY_007] using the CT SAE Report Form .
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in
Section 8.3.[ADDRESS_584857] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24
hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_584858] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAE
s reported by  [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs.   Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization , the event is otherwise explained, 
or the participant is lost to follow
-up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 

PF-[ADDRESS_584859] be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will c omply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRB
s/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the study  intervention under stud y during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental exposure during pregnancy :  
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by [CONTACT_457942] y drug.
The investigator must report ED P to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 42should include the anticipated date of delivery  (see below for information related to 
termination of pregnan cy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of stud y intervention and until [ADDRESS_584860] dose.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the 
CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as
a 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clin ically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are consi dered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_584861] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_19991].  
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred.  The 
information must be reported using the CT SAE Report Form.  When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintain ed in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use.  However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact [CONTACT_19994] , which may  or may  not lead to the occurrence of an AE. Such persons 
may include healthcare provider s, famil y members, and other roles that are involved in the 
trial participant’s care.
The investigator must report occupational exposure to [COMPANY_007] Safet y within 24 hours of t he 
investigator’s awareness regardless of whether there is an associated SAE.  The information 
must be reported using the CT SAE Report Form.  
Since the information does not pertain to a 
participant enrolled in the study , the information is not recorded on a CRF; however, a copy  
of the completed CT SAE Report Form is maintained in the investigator site file .
8.3.6. Cardiovascular and Death Events
Not Applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not Applicable.
8.3.8. Adverse Events of Special Interest
Not Applicable.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Not Applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 
24
Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Wheth er or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on theAE pag e of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_584862] SAE Report 
Form only when associated with an SAE.
8.4.Treatment of Overdose
For this study , any  dose of PF -06865571 greater than 1800 mgwithin a 24- hour time period 
will be considered an overdose.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 45Sponsor does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_44686] m onitor within 24 hours .
2.Closely  monitor the participant for an y AEs/SAE sand laboratory  abnormalities for at 
least 5 half-lives or 28 calendar day s after the overdose of PF -06865571 (whichever 
is longer).  
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to Sa fety only when associated with a nSAE.
5.Obtain a blood sample for PK anal ysis as soon as possible upon identification of 
overdose . 
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_457943].
8.5.Pharmacokinetics 
The samples collected for PK ( PF-06865571 concentration), radioactivity  (total 14C) and/or 
metabolite profiling assessment must be processed and shipped as indicated in the 
instructions provided to the investigator site to maintain sample integrit y.Any deviations 
from the sample handling procedure (eg, sample collection and processing steps, interim 
storage or shippi[INVESTIGATOR_19944]), including an y actions taken, must be docum
ented and 
reported to the sponsor.  On a case -by-case basis, the sponsor may  make a determination as 
to whether sample i ntegrity  has been compromised.
Samples collected for PK, radioactivity  and/or metabolite profiling /IDmay also be used to 
evaluate safet y or efficacy aspects related to concerns arising during or after the study, for 
metabolite identification and/or evaluation of the bioanaly tical method, or for other internal 
exploratory  purposes.
Genetic anal yses will not be performed on these samples 
unless consent for this was included 
in the informed consent.  
Participant confidentiality will be maintained.
8.5.1. Period 1 Plasma for Analysis of Total 14Cand Metabolite Profiling/ID
During Period 1, blood samples of approximately  4mLfor total 14C and 10 mL for 
metabolite profiling/ ID,to provide approximately  1.6mL and 4 mL of plasma , respectively ,
will be collected into appropriatel y labeled tubes containing K 2EDTA at times specified in 
theSchedule of Activ ities.  Instructions for the collection and handling of biological samples 
will be provided in the lab oratory manual or b y the sponsor. The actual date and time 
(24-hour clock time) of each sample will be r ecorded.

PF-[ADDRESS_584863] nominal time relative to dosing.  Collection of 
samples up to and including 10 hours after dose administratio nthat are obtained within 
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60 - minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF.  Collection of samples more than 10 hours after dose
administration that are obtained ≤
1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source docu ment and theCRF. This protocol deviation window does not apply  to 
samples to be collected more than 10 hours after dose administration at outpatient/follow -up 
visits with visit windows.
Details regarding the collection, processing, storage and shippi[INVESTIGATOR_007] o f the blood samples will 
be provided in the lab manual.
8.5.2. Period 2 Plasma for Analysis of [14C]PF-06865571 (After IV Administration )
During Period 2, blood samples of approximately  4mL,to provide approximately  1.6mL of 
plasma, for PK analy sis of radiolabeled [14C]PF-06865571 will be collected into 
appropriatel y labeled tubes containing K 2EDTA at times specified in theSchedule of 
Activi ties.  Instructions for the collection and h andling of biological samples will be provided 
in the laboratory  manual or by  [CONTACT_456].  The actual date and time (24 -hour clock time) of 
each sample will be recorded.
The actual times may  change, but the number of samples will remain the same.  All eff orts 
will be made to obtain the samples at the exact nominal time relative to dosing.  Collection of 
samples up to and including 10 hours after dose administration that are obtained within 
10%
of the nominal time relative to dosing (eg, within 6 minutes of a 60-minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF.  Collection of samples more than 10 hours after dose
administration that are obtained ≤
1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF. This protocol deviation window does not apply  to 
samples to be collected more th an10hours after dose administration at outpatient/follow -up 
visits with visit windows.
Windows defined for times relative to oral dosing are intended to ensure accurate sample 
collection as required for the anal ysis of both oral and IV data.
Details regarding the collection, processing, storage and shippi[INVESTIGATOR_74034].
Samples collected for measurement of plasma radiolabeled [14C]PF-06865571 concentrations 
will be anal yzed using a validated quantitative AM S method after chromatographic 
separation of the parent compound in compliance with applicable SOPs.   

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 478.5.3. Plasma for Analysis of Unlabeled PF -06865571 (Periods 1 and 2)
During Period s 1and 2 , blood samples of approximately  3mL to provide approximately  1.2
mL of plasma for PK 
analy sis of unlabeled PF-06865571 will be collected into appropriatel y 
labeled tubes containing K2EDTA at times specified  in the Schedule of Activ ities.  
Instructions for the collection and handling of biological samples will be provided in the 
laboratory  manual or by  [CONTACT_456].  The actual date and time (24 -hour clock time) of each 
sample will be recorded.
The actual times may  change, but the number of samples will remain the same.  All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing.  Collection of 
samples up to and including 10 hours after dose administration that are obtained within 
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60 -minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF.  Collection of samples more than [ADDRESS_584864] ration that are obtained ≤
1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF. This protocol deviation window does not a pply to 
samples to be collected more than 10hours after dose administration at outpatient/follow -up 
visits with visit windows.
Details regarding the collection, processing, storage and shippi[INVESTIGATOR_74034].
Samp les collected for measurement of plasma concentrations of PF- 06865571 will be 
analyzed using a validated anal ytical method in compliance with applicable SOPs.
8.5.4. Urine for Analysis of Total 14C (Oral and IV) and Metaboli teProfiling /ID
Urine will be collected for determination of total 14C measurement and metabolite 
profiling/ID following oral administration of [14C]PF-06865571 ( Period 1 only) and for 
determination of total 14C measurement following IV administration of 
[14C]PF-06865571 
(Period 2 only), at predose and at post dose intervals as specified in the Schedule of 
Activi ties.  
Each participant will empty
 his bladder just prior to dosing on Day  1 and an aliquot f rom this 
collection will be used as “urine blank”.  During the entire collection period, the urine 
collection container should be refrigerated. At the end of each urine collection period, the 
total volume will be measured and recorded.  All urine aliquots should be collected using a 
new pi[INVESTIGATOR_457926].  All urine samples within each 
collection interval will be mixed thoroughly  before aliquoting.  
Details regarding the collection volume, processing , storage and shippi[INVESTIGATOR_457927].

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 488.5.5. Feces for Analysis of Total 14C (Oral and IV) and Metaboli teProfiling/ID
Feces will be collected for determination of total 14C measurement and metabolite 
profiling/ID followi ng oral administration of [14C]PF-06865571 in Period 1at times 
specified in the Schedule of Activi ties.  Feces will be collected following IVadministration 
of [14C]PF-06865571 in Period 2at times specified in theSchedule of Activi ties,and may  be 
analyzed for total 14C and/or [14C]PF-06865571 determination and/or metabolic profiling /ID
if the fraction of dose excreted as parent in feces of Period 1 is 0.25 greater than unabsorbed 
drug (1 -Fa), indicating biliary  and/or GI excretion ma y be a major pathway
 for parent drug 
clearance (e.g. greater than 25% of total clearance) .
Fecal voids will be collected at the clinic and immediatel y frozen.  The sample will be 
labeled and frozen at approximately  -20C. 
Total fecal mass is to be recorded for each 24-hour period. Each bowel movement must be 
collected.  Time and date must be recorded.  
In the event of diarrhea during the stud y, all diarrhea, including an y swabbing and 
contaminated linen, should be collecte d, labeled, and stored in appropriate containers 
at 
-20C for possible analysis of radioactivity .  Following completion of radioanaly sis and 
subsample collections for metabolite profiling /ID, the remaining bulk fecal homogenate will 
be discarded upon appro val from the sponsor.
Details regarding the collection, processing, storage and shippi[INVESTIGATOR_457928].
All feces samples must be processed and shipped as indicated to maintain sample integrity .  
Any deviations fro m the processing steps, including an y actions taken, must be documented 
and reported to the sponsor.  On a case -by-case basis, the sponsor may  make a determination 
as to whether sample integrit y has been compromised.  An y sample deemed outside of 
established stability , or of questionable integrit y, will be considered a protocol deviation.
8.5.6. Emesis
If emesis occurs within 24 hours after oral administration of [14C]PF- 06865571 ( Period 1
only), then the vomitus must be collected and stored for a radioactivity  assessment.  All 
emesis including an y swabbing, contaminated linens and facial tissues used to collect bodily 
discharge; eg, nose bleeding clean -up tissue and any  emesis related clea n-up is to be 
collected and stored at -20Cfor possible anal ysis of radioactivity . 
Details regarding the collection, processing, storage and shippi[INVESTIGATOR_457929].  
8.6.Pharmacodynamics
Pharmacod ynamic parameters are not evaluated in this study .

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 498.7.Genetics
8.7.1. Specified Genetics
Genetics (specified anal yses) are not evaluated in this study .Any genetic analy sis, if 
conducted, will not be part of this study  report.
8.7.2. Banked Biospecimens for Genetics
A 2mL blood sample optimized f or DNA isolation Prep D 1.5will be collected as local 
regulations and IRBs/ECs allow.
Banked Biospecimens may be used for research related to thestudy  intervention (s)and/or
NAFLD/NASH .  Genes and other analy tes (eg ,proteins, RNA, nondrug metabolites) may  be 
studied using the banked samples. 
See Appendix 5for i
nformation regarding genetic research.  Details on processes for 
collection and shipment of these samples can be fou nd in supporting documentation .
8.8.Biomarkers
Collection of samples for biomarker research is also part of this study . 
The following sample for biomarker research are required and will be collected from all 
participants in this study  as specified in the Schedule of Activi ties:
Whole blood (Prep B1) Banked Biospecimen optimized for plasma
8.8.1. Specified Gene Expression (RNA) Research
Specified gene expression (RNA) research is not included in this study .
8.8.2. Specified Protein Research
Specified protein research is not included in this study .
8.8.3. Specified Metabolomic Research
Specified metabolomic research is not included in this study .
8.8.4. Banked Biospecimens for Biomarkers
Additional Ban ked Biospecimens in this study  are:
10mL whole blood Prep B1 optimized for plasma
Banked Biospecimens will be collected as local regulations and IRB/ECs allow.  
Banked Biospecimens may be used for research related to the study  intervention (s)and 
NAFLD /NASH .  Genes and other analy tes (eg ,proteins, RNA, nondrug metabolites) may  be 
studied using the banked samples. 

PF-06865571
Protocol C2541007Final Protocol, 11 Dec 2020
PFIZER CONFIDENTIAL
Page 50See Appendix 5 for information regarding genetic research.  Details on processes for 
collection and shipment of these samples can be found in supporting documentation. 
8.9. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.10. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a SAP, which will be maintained by [CONTACT_456].  The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
No statistical hypothesis is tested in this study.
9.2. Sample Size Determination
A sample size of [ADDRESS_584865] sample 
size for ADME Mass Balance studies and radiolabeled tracer studies.  This sample size was not chosen based on any empi[INVESTIGATOR_457930].
Participants who withdraw from the study, for non-safety reasons, may be replaced if the 
number of participants with evaluable data is less than 4.
9.3. Analysis SetsFor purposes of analysis, the following analysis sets are defined:
Participant
Analysis SetDescription
Evaluable All participants assigned to study intervention and who take at 
least [ADDRESS_584866] received 1 dose of [14C]PF-[ADDRESS_584867] 
evaluable total radioactivity  concentration (urinary and fecal) data 
and who had no protocol deviations or AEs (such as vomiting of 
the dose, diarrhoea or severe constipation) that may  have affected 
the extent of excretion analy sis.
PK Concentration The PK c oncentration population for PF -[ADDRESS_584868] 1 measurable concentration of PF-06895571. 
The PK concentration population for 14C is defined as all
participants dosed with [14C]PF-[ADDRESS_584869] they actuall y received.
9.4. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.4.1. Primary Endpoint(s)
[IP_ADDRESS]. Extent of Excretion (Period 1)
Radioactivity  excreted in urine and/or feces will be reported as the percentage of the 
administered radioactivity excreted at each time interval , cumulativel y through that interval 
and the total percent of dose recovered 
in urine and/or feces. 
Percent recovery  and cumulative recovery  of total radioactivity  in urine , feces and emesis
(if an y)will be determined based on total administered dose.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 52Note: W hile the total percentage of dose excreted isthe primary  endpoint ,the percentage of 
the administered radioactivity  excreted at each time interval andcumulatively  through that 
interval are tertiary  endpoints. 
Individual participant and median data profiles will be graphicall y presented for the 
cumulative recovery  of radioactivity  in urine, feces and their combination.  The total 
recovery  of radioactivit y in urine, feces and their combination will be listed and summarized 
using descriptive statistics.  Where possible, the rate of excreti on of radioactivity  will be 
estimated.
[IP_ADDRESS]. Metabolic Profiling /Identification ( Period 1 )
Plasma, urine and fecal samples will be anal yzed for metabolites of PF-06865571 .  Major 
metabolites of PF-06865571 in plasma, urine, and feces following oral dose of [14C]PF-
06865571 will be identified if possible.  Results of the metabolic profiling analy sis will be 
detailed in a separate report and will be summarized within the CSR.
9.4.2. Secondary Endpoint(s)
[IP_ADDRESS]. Pharmacokinetic Parameters
[IP_ADDRESS].1. Plasma
The PF-
06865571 PK parameters following a single dose administration of unlabeled 
PF-06865571 (oral) and microtracer dose of [14C]PF-06865571 (oral and IV) will be derived, 
where appropriate, from the concentration -time profiles as outlined below:
Parameters for total 14C (14C oral microtracer) will be derived for Period 1 only;
Parameters for PF -06865571 after oral dose s of 14C oral microtracer and unlabeled 
PF-06865571 for Periods 1 and 2, respectivel y andfor [14C]PF- [ADDRESS_584870] 
quantifiable concentration (C last)Linear/Log trapezoidal rule
AUC last(dn) Dose normalized AUC last AUC last/Dose
AUC infa Area under the plasma 
concentration -time profile from 
time zero extrapolated to infinite 
timeAUC last+(Clast*/k el), where C last* is the 
predicted plasma concentration at the 
last quantifiable time point estimated 
from the log -linear regression analy sis
AUC inf(dn)aDose normalized area under the 
plasma concentration -time profile 
from time zero extrapolated to 
infinite timeAUC inf/Dose

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 53Parameter Definition Method of Determination
Cmax Maximum plasma concentration Observed directl y from data
Cmax(dn) Dose normalized maximum plasma 
concentration.Cmax/Dose
Tmax Time for C max Observed directl y from data as time of 
first occurrence
t½a Terminal elimination half- life Loge(2)/k el, where k elis the terminal 
phase rate constant calculated by  a linear 
regression of the loglinear concentration
time curve.  Onl y those data points 
judged to describe the terminal loglinear
decline will be used in the regression
CL/Fa(oral) Apparent clearance following oral 
administrationDose/AUC inf
CLa(IV) Systemic clearance Dose/AUC inf
Vz/Fa(oral) Apparent volume of distribution 
following oral administrationDose /(AUC inf*kel)
Vssa(IV) Steady -state volume of distribution 
following IV infusionVss=CL × [MRT -(infusion time/2)]
where MRT is the Mean Residence Time and is
calculated as AUMC inf/AUC inf
a.If data permit .
Actual PK sampling times will be used in the derivation of PK parameters, defined relative to 
the oral dose for the oral parameters and relative to the start of the 15-minute IV infusion for 
the IV parameters.  Actual administered 14C doses will be used for the total 14C and 
[14C]PF-
06865571 PK parameter calculations.
Plasma PK parameters above will be listed and summarized descriptively  by [CONTACT_242947] (total 
14C, unlabeled PF-06865571 , and [14C]PF-06865571) and treatment, as applicable.  The
descriptive summary , concentration and PK parameters will be presented in appropriate
tables and figures .  
[IP_ADDRESS].2. Absolute 
Oral B ioavailability (F)
F will be estimated as the ratio of adjusted geometric means of dose -normalized AUC inf(if 
data permit, otherwise AUC last) for oral unlabeled PF -06865571 and IV labeled 
14C-PF-06865571 in plasma (from Perio d 2 onl y) which is equivalent to the following 
equation:
F = [ PF-06865571_AUC po/ [14C]PF-06865571 _AUC iv]×[ [14C]PF-06865571_Dose iv/ 
PF-
06865571_Dose po]

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 54Geometric Mean Ratio and 90% confidence interval: Natural log transformed AUC inf(dn) 
(if data permit) and AUC last(dn) from Period [ADDRESS_584871].  Estimates of 
the adjusted (least squares) mean differences (Test -Reference) and the corresponding 
90% CI will be obtained from the model.  The adjusted mean differences and 90% CI s 
for the differences will be exponentiated to provide estimates of the ratio of adjusted 
geometric means (Test/Reference) and 90% CI for the ratio.  IV [14C]PF-[ADDRESS_584872] formulation. 
[IP_ADDRESS].3. Fraction Absorbed (Fa)
[IP_ADDRESS].3.1. Urine Parameters
Following urine parameters will be calculated following single dose administration of a 
microtracer dose of [14C]PF-06865571 (oral and IV administration).  Residual 14Clevels 
from Period 1 will be accounted for using an appropriate method, based on AMS principles 
and methodology .
Parameter Definition Method of Determination
Total 14C_Urine_PO Total radioactivity excreted into the urine 
postdose follow ing oral administration of 
[14C]PF-06865571 microtracer doseSum of [14C urine concentration × sample 
volume] for each collection interval
Total 14C_Urine_IV Total radioactivity excreted into the urine 
following IV administration of 
[14C]PF-06865571 microtracer doseSum of [14C urine concentration × sample 
volume] for each collection interval
%14C_Urine_PO Percent of the radioactive dose administered 
that is excreted in the urine follow ing oral 
administrationTotal 14C_Urine_PO/14CDose po × 100
Where 14C Dose pois the dose of 14C 
following oral administration of 
[14C]PF-06865571
%14C_Urine_IV Percent of the radioactive dose administered 
that is excreted in the urine follow ing IV 
administrationTotal 14C _Urine_IV/14CDose iv× 100
Where 14C Dose ivis the dose of 14C 
following IV administration of 
[14C]PF-06865571
Total urine 14C amounts, percent 14C dose will be listed by  [CONTACT_3148] ( oral in Period 1and IV 
in Period 2) and summarized using descriptive statistics.  
[IP_ADDRESS].3.2.
Calculation of Fa
Fa will be estimated as the ratio of the adjusted geometric means of % of administered 
radioactive dose excreted into the urine following oral and IV administration of 
[14C]PF-06865571 microtracer dose over the same collection time (up to 48hours post dose) 
in Periods 1 and 2, respectively : 
Fa = [% 14C_Urine_PO/% 14C_Urine_I V];

PF-06865571
Protocol C2541007Final Protocol, 11 Dec 2020
PFIZER CONFIDENTIAL
Page 55•Geometric Mean Ratio and 90% confidence interval: Natural log transformed % Total 
14C in Urine from Period [ADDRESS_584873].  Estimates of the adjusted (least squares) mean differences (Test-Reference) and the corresponding 90% CI will be obtained from the model.  The adjusted mean differences and 90% CIs for the differences will be exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CI for the ratio.  Total 
14C_Urine_IV is the Reference 
formulation and Total 14C_Urine_PO is the Test formulation. 
Theoretically Fa would be expected to be greater than F. In the event that F is estimated to be 
greater than Fa, the greater of the 2 values will be used to represent the fraction of PF-06865571 absorbed. PF-06865571 will be considered highly permeable if either F or Fa is greater than 0.85 (as per BCS guidance).
9
9.4.3. Tertiary/Exploratory Endpoint(s)
 
 
 
 
[IP_ADDRESS]. Cumulative Rate of Excretion (Period 1)
See Section [IP_ADDRESS] .
[IP_ADDRESS]. Pharmacokinetics Parameters (Unlabeled PF-06865571 - Period 2)
See Section [IP_ADDRESS].1 .
9.4.4. Other Safety Analyses
All safety analyses will be performed on the safety population.
AEs, ECGs, BP, pulse rate, and safety laboratory data will be reviewed and summarized on 
an ongoing basis during the study to evaluate the safety of participants.  Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described.  Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
Medical history and physical examination and neurological examination information, as 
applicable, collected during the course of the study will be considered source data and will not be required to be reported, unless otherwise noted.  However, any untoward findings identified on physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. Data collected at Screening that are used for inclusion/exclusion criteria, such as laboratory CCI
PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 56data, ECGs ,and vital signs , will be considered source data, and will not be required to be 
reported , unless otherwise n
oted.  Demographic data collected at s creening will be reported .
9.4.5. Other Analyse (s)
Pharmacogenomic or biomarker data from Banked Biospecimens may be collected during or 
after the trial and retained for future anal yses; the results of such analy ses are not planned to 
be included in the CSR.
9.5.Interim Analyses
No formal interim anal ysis will be conducted for this study . As this is an open -label
study ,the sponsor may  conduct unblinded reviews of the data during the course of the study  
for the purpose of safet y assessment and/or support ingclinical development. 
9.6.Data Monitoring Committee or Other Independent Oversight Committee
This study  will not use a DMC . 

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 5710. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_107095]/EC by  [CONTACT_107096]/EC before the study  is 
initiated .
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the follo wing:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y finding s as required by  
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .  
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participant
s against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 5810.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant and answer al l questions regarding the study .  The participant should be given 
sufficient time and opportunity  to ask questions and to decide whether or not to participate in 
the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, HIPAA requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  partici pant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The par ticipant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her m edical records may  be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study
participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D.
Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participant.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 59Unless prohibited by  [CONTACT_20006]/EC decision, the IC D will contain a separate 
section that addresses the use of samples for optional additional research.  The optional 
additional research does not require the collection of an y further samples. The investigator 
or authorized designee will explain to each participant the objectives of the additional
research. Participants will be told that they  are free to refuse to participate and may  
withdraw their consent at any  time and for any  reason during the storage period. A separate 
signature [CONTACT_22862] a participant's agreement to allow specimens to be 
used for additional research. Participants who decline to participate in this optional
additional research will not provide this separate signature .
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authoriz ed study  staff have access.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site will be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transfer red. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant- specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record identification . In 
case of data transfer, the sponsor will protect the confidentiality  of participants’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Dissemin ation of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on 
www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries i n accordance with applicable local 
laws/regulations.  In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanc ed, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 60www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studie s (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted.  These r esults are 
submitted for posting in accordance with the format and timelines set forth by  [INVESTIGATOR_28936] l aw.
EudraCT
[COMPANY_007] posts clinical trial r esults on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which a ny data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website.   Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authoriz ation applications submitted via the centrali zed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient -level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  com pletion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, incl uding individuals 
requesting access for commercial/competitive or legal purposes.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 6110.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
The investigator must maintain accurate documentation (source data) that supports the 
informati on entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.   This 
verification may  also occur after study  completion.  I t is important that the investigator(s
) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk- based initiatives in operations and quality  
such as risk management and mitigation strategies and analytical r isk-based monitoring), 
methods, responsibilities ,and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the S tudy 
Monitoring P lan.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other stud y 
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulation s or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all sy stems.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 62The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copi[INVESTIGATOR_19946].  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agent s with an opportunity  to review and comment on responses to any  such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected.   Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . 
Also, current medical records must be available.
Definition of what constitutes source data can be found in Study  Monitoring Plan .
Description of the use of computerized sy stem is documented in the Data Management Plan .
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon 
study  completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to thesponsor 
or designee/ CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 63Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications 
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] -intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications relating to the study , the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for p ublication of the over all study  results 
covering all i nvestigator sites.   In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data.
  In this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 6410.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualified medical personn el for the 
study  is documented in the study  contact [CONTACT_168069]. 
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participant s are provided with a cont act card at the time of informed 
consent .  The contact [CONTACT_4662], at a minimum, protocol and study  intervention
identifiers, participant numbers, contact [CONTACT_22850], and contact 
[CONTACT_4664] a contact [CONTACT_214362] a medical question or problem originating from another healthcare 
professional not involved in the participant ’s participation in the study .  The contact [CONTACT_107101] b y investig ator staff if they  are seeking advice on medical questions or 
problems; however, it should be used only
 in the event that the established communication 
pathway s between the investigator site and the study  team are not available.  I t is therefore 
intended t o augment, but not replace, the established communication pathway s between the 
investigator site and the study  team for advice on medical questions or problems that may  
arise during the stud y.  For sites other than a [COMPANY_007] CRU, the contact [CONTACT_457944] i ntended 
for use b y the participant directly , and if a participant calls that number, he or she will be 
directed back to the investigator site.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 6510.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory tests will be performed at times defined in the S chedule of 
Activi tiesof this protocol.  Additional laboratory  results may be reported on these samples as 
a result of the method of anal ysis or the ty pe of analy zer used by  [CONTACT_457945] ,or as 
derived from calculated values.  These additional tests would not require additional 
collection of blood.  Unscheduled clinical laboratory  measurements may  be obtained at an y 
time during the stud y to assess an y perceived safety  issues. Participants may  undergo random 
urine drug 
and cotinine testing at the discretion of the investigator
Table 1. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils 
(Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN
Serum creatinine
Serum g lucose 
(fasting)
Calcium
Sodium
Potassium
Chloride
Total 
CO 2(bicarbonate)
AST, ALT
Total bilirubin
Direct ( conjugated) 
bilirubina
Indirect 
(unconjugated) 
bilirubina
Alkaline phosphatase
Uric acid
Albumin
Total proteinpH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte 
esterase
Urobilinogen
Urine bilirubin
MicroscopybAt screen ingonly unless 
otherwise stated :
Urine drug screening , 
Period 1, Day -1c
Urine cotinine screening , 
Period 1, Day -1
HBsAg
HCV Ab
HIV
COVID -19 testingd
a.To be assessed as reflex tests when total bilirubin is > ULN.
b.Only if urine dipstick is positive for blood, protein, nitrites ,or leukocyte esterase.
c.The minimum requirement for drug screening includes cocaine, THC, opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], 
benzodiazepi[INVESTIGATOR_1651], and amphetamines (others are site and study specific).
d.Testing for COVID -19 pathogen (SARS -CoV -2) by [CONTACT_159754] R will be performed at each visit to the CRU 
(Screening and Admission). For participants admitted for residence in the CRU, a subsequent 
COVID -[ADDRESS_584874] will be performed 2x/week at a minimum.
Investigators must document their review of each laboratory  safet y report.
Any remaining serum/plasma from samples collected for clinical safet y lab oratory  
measurements at baseline and at all times after dose administration may be retained and 
stored for the duration of the study .  Upon completion of the study , these retained safet y 
samples may  be used for the assessment of exploratory  safet y biomarkers or unexpected 

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 66safet y findings .  These data will not be included in the CSR.  Samples to be used for this 
purpose will be shipped to either a [COMPANY_007] -approved BBS facility  or other designated 
laboratory  and retained for up to 1year following the completion of the study .

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 6710.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Defini tion
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or 
not considered related to the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including 
an abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator. Any 
abnormal laboratory  test results that meet any  of the conditions below must be 
recorded as an AE:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition including either 
an increase in fre quency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration 
even though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported 
as an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 68Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  
[CONTACT_19448]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms 
of the disease/disorder being studied, unless more severe than expect ed for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if s erious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatie nt hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment th at would not have been appropriate in the phy sician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 69Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disab ility/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, naus ea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or sc ientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_402880]. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording adverse events on the CRF 
and for reporting serious adverse events on the CT SAE Report Form to [COMPANY_007] Safet y.  
These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) nonserious AEs; 
and (3) exposure to the study  intervention under study  during pregnancy  or 
breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF .  When the same data are collected, the forms must 
be completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE informati on.

PF-[ADDRESS_584875] SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding, and 
occupational exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Occupational exposure is 
not recorded.All (and EDP 
supplemental form for 
EDP)  
Note:  I nclude all SAEs
associated with exposure 
during pregnancy  or 
breastfeeding. Include all 
AEs/SAEs associated with 
occupational exposure.
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Saf ety in lieu of completion of the CT SAE Report 
Form /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagno sis 
(not the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal 
discomfort and not interfering with every day activities.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 71Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that preven ts normal every day activities. An AE that is 
assessed as severe should not be confused with a nSAE.  Severe is a category 
utilized for rating the intensity  of an event; and both AEs and SAEs can be 
assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.
The investigator will use clinical judgment to determine th e relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator wi ll also consult the IB and/or product information, for 
marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event b efore the initial transmission of the SAE data to the 
sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 72The causality  assessment is on e of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for 
reporting purposes, a s defined by  [CONTACT_456] .  In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator 
must record this causal relationship in the source documents and CRF, and report 
such an assessment in the dedicated se ction of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations as medically  indicated or as 
requested b y the sponsor to elucidate the nature and/or causalit y of the AE or 
SAE as fully  as possible. This may include additional laboratory  tests or 
investigations, histopathological examinations, or consultation with other 
healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 
hours of rece ipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is com pleted at a given site, the electronic data collection tool 
will be taken off -line to prevent the entry  of new data or changes to existing data.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 73If a site receives a report of a new SAE from a study  participant or receives 
updated data on a previously  repo rted SAE after the electronic data collection 
tool has been taken off -line, then the site can report this information on a paper 
SAE form (see next section) or to [COMPANY_007] Safet y by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent b y overnight mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 7410.4. Appendix 4: Contraceptive Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
No contraception methods are required for male participants in this study  as the calculated 
safet y margin is ≥100- fold between the estimated maternal exposure due to seminal transfer 
and the NOA EL for serious manifestations of developmental toxicity  in nonclinical studies.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 7510.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease . Therefore, where local 
regulations and IRB s/ECsallow, a blood sample will be collected for DNA anal ysis.
The scope of the genetic research may  benarrow (eg, 1or more candidate genes ) or
broad (eg,the entire genome ),as appropriate to the scientific question under 
investigation.
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the response to study  intervention or study  interventions of this class to 
understand treatments for the disease( s) under study  or the disease(s) themselves.
The results of genetic analy ses may  be reported in the CSR or in a separate study  
summary , or may  be used for internal decision making without being included in a 
study  report.
The sponsor will store the DNA sam ples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained as indicated:
Samples for banking will be stored indefinitel y or for an other period as per local 
requirements.  
Participant s may  withdraw their consent for the storage and/or use of their B anked 
Biospecimens at any  time by  [CONTACT_7328] a request to the investigator; in this case, any  
remaining material will be destro yed.  Data already generated from the samples will 
be retained to p rotect the integrit y of existing analyses.   
Banked Biospecimens will be labeled with a code.  The key  between the code and the 
participant ’s personally  identify ing information (eg ,name, address) will be held at the 
study  site and will not be provided to the sample bank.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 7610.6. Appendix 6: Liver Safety: Suggested Actions and Follow- up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some participant s, transaminase elevations are a harbinger of a 
more ser ious potential outcome.  These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI.  
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more fr equently  to determine if they  are an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks.  The increase in TBili ty pi[INVESTIGATOR_214318]/AL T is/are stil l elevated above 3 ×ULN (ie, AST/AL T and TBili values will be 
elevated within the same lab oratory sample).  In rare instances, by  [CONTACT_20024], AST/ALT values might have decreased.  This occurrence is still regarded as a 
potentia l DILI.  Therefore, abnormal elevations in either AST OR ALT in addition to TBili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered important medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions.  Participant s who present 
with the follo
wing laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is sma ller).

PF-[ADDRESS_584876]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_584877] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acids, and alkaline phosphatase.  Consideration s hould 
also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood 
for further testing, as needed, for further contemporaneous anal yses at the time of the 
recognized initial abnormalities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen /paracetamol (either by  [CONTACT_20025] a 
coformulated product in prescription or over -the-counter medications) , recreational drug, 
supplement (herbal) use and consumption, famil y history , sexual history , travel history , 
history  of contact [CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or 
allergic disease, and potential occupational exposure to chemicals, should be collected.  
Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  
tract) and collection of serum sample s for acetaminophen/paracetamol drug and/or protein 
adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  
Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of avail ability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and hav e excluded an alternative etiology .

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 7810.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by60msecfrom 
baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’
duration.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive 
ventricular complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 ms ec).
New -onset right bundle b ranch block (QRS >120 msec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented 
periods of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an 
escape rh ythm that is below t he AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_584878] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s uprave ntricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 79Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm 
(heart rate <40 bpm), accelerated idioventricular rhy thm ( HR > 40bpm to
<100 bpm), and monomorphic/poly morphic ventricular tach ycardia (HR 
>100 bpm (such as torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with ra pid ventricular response requiring 
cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SA Es.

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 8010.8. Appendix 8: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
Abs absolute
ACCi acetyl-CoA carbox ylaseinhibitor
ADME absorption, distribution, metabolism, and excretion
AE adverse event
Aetau cumulative amount of drug recovered unchanged in the urine 
during a dosing interval
ALT alanine aminotransferase
AMS accelerator mass spectrometry
API [INVESTIGATOR_457931] 24 area under the concentration -time curve from time 0 to 24 hours
AUC inf area under the concentration -time curve from time 0 to infinity
AUC inf(dn) dose normalized AUC inf
AUC last area under the concentration -time curve from [ADDRESS_584879](dn) dose normalized AUC last
AUC tau area under the concentration -time curve at stead y state over the 
dosing interval 
AUMC inf area under the first moment curve from time [ADDRESS_584880] cancer resistance protein
BCS Biopharmaceutics Classification Sy stem
BE bioequivalence
BID twice a day
BMI body  mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CL/F apparent clearance following oral administration
CL r renal clearance
Clast last quantifiable concentration 
Cmax maximum observed concentration

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 81Abbreviation Term
Cmax(dn) dose normalized C max
COVID -19 coronavirus disease 2019
CO2 carbon dioxide (bicarbonate)
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR Clinical Study  Report
CT clinical trial
CYP cytochrome P450
DAG diacylglycerol
DDI drug-drug interaction
DGAT diacylglycerol acyltransferase
DILI drug-induced liver injury
DMC data monitoring committee
DNA deox yribonucleic acid
DNL de novo lipogenesis
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form
EDP exposure during pregnancy
EDR extemporaneous dispensing record
EMA European Medicines Agency
ET early termination
EU European Union
EudraCT European Clinical Trials Database
F absolute oral bioavailability
Fa fraction absorbed
Fg fraction escapi[INVESTIGATOR_457932] -pass elimination
F/U follow up
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
HBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency virus
HR heart rate
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation
ICRP International Commission on Radiological Protection
ID identification

PF-[ADDRESS_584881]
IV intravenous
K2EDTA dipotassium ethy lene diamine tetraacetic acid 
LBBB left bundle branch block
LC/MS liquid chromatograph y tandem mass spectrometry
LFT liver function test
Loge natural logarithm
MATE multidrug and toxic compound extrusion transporter
mBCRP mouse breast cancer resistance protein
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDR multi -drug resistance protein
mrem millirem
MRT mean residence time
msec millisecond
N/A not applicable
Nab neutralizing antibodies
NAFLD nonalcoholic fatt y liver disease 
NASH nonalcoholic steatohepatitis 
nCi nanocurie
NOAEL no-observed -adverse -effect level
OCT organic cation transporter
PCR polymerase chain reaction
PD pharmacod ynamic(s)
PE physical examination
P-gp P-glycoprotein
PI [INVESTIGATOR_19959](s)
PO orally
PT prothrombin time
PVC premature ventricular contraction/complex
P1 Period 1
P2 Period 2
QA quality  assurance
QTc corrected QT
QTcF corrected QT ( Fridericia method)
Q8H every  [ADDRESS_584882] upper limit of normal
US [LOCATION_002]
Vss steady -state volume of distribution following IV infusion
Vz/F apparent volume of distribution following oral administration
VLDL very low densit y lipoprotein
WBC white blood cell

PF-06865571
Protocol C 2541007
Final Protocol, 11Dec2020
PFIZER CONFIDENTIAL
Page 8411.REFERENCES
1. Yen CL , Stone SJ, Koliwad S, et al.  Thematic review series: gl ycerolipi[INVESTIGATOR_805]. DGAT
enzy mes and triacy lglycerol biosy nthesis.  J L ipid Res .2008;49(11):2283 -301.
2. Buhman KK, Smith SJ, Stone SJ, et al.  DGAT1 is not essential for intestinal 
triacy lglycerol absorption or chy lomicron sy nthesis.  J Biol Chem .
2002;277(28):[ZIP_CODE]-9.
3. Cases S, Stone SJ, Zhou P, et al.  Cloning of DGAT2, a second mammalian 
diacy lglycerol acy ltransferase, and related family members.  J Biol Chem .
2001;276(42):[ZIP_CODE]-6.
4. Choi CS, Savage DB .Suppression of diacy lglycerol acy ltransferase -2 (DGAT2), but 
not DG AT1, with antisense oligonucleotides reverses diet -induced hepatic steatosis and 
insulin resistance. J Biol Chem. 2007;282(31):[ZIP_CODE]-88.
5. Yu XX, Murray  SF, Pandey  SK, et al.  Antisense oligonucleotide reduction of DGAT2 
expression improves hepatic steatosis and h yperlipi[INVESTIGATOR_310774].  Hepatology.
2005;42(2):362 -71.
6. Liu Y, Millar JS, Cromley  DA, et al.  Knockdown of acy l-CoA:diacy lglycerol 
acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion 
in mice.  Biochim Biophys Acta .2008;1781(3):97 -104.
7. International Commission on Radiological Protection. 1990 Recommendations of the 
International Commission on Radiological Protection. Ann. I CRP 1991. 21, 1–201.
8. Abdelmalek MF, Lazo M, Horska A, et al. Fatt y Liver Subgroup of Look, A. R. G., 
Higher dietary  fructose is associated with impaired hepatic adenosine triphosphate 
homeostasis in obese individuals with ty pe 2 diabetes. Hepatology .2012;56:952 -
60.
9. FDA Guidance “Waiver of In Vivo Bioavailability  and Bioequivalence Studies for 
Imm ediate -Release Solid Oral Dosage Forms Based on a Biopharmaceutics
Classification Sy stem”. December 2017.
10. Banholzer ML, Wandel C, Barrow P, et al. Clinical trial considerations on male 
contraception and collection of pregnancy  information from female partner: update. 
Clin Transl Med. 2016;5(1)(Dec):23.
11. ICH Topic M3 (R2). Non- clinical safety  studies for the conduct of human clinic al trials
and marketing authorization for pharmaceuticals. International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use (2009).
